Friday 6 November 2026 Export RVMD’s income statement to Excel — free account

Revolution Medicines, Inc.

Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.

Revenue: +1,188.7%
EPS: −18.0%
Free cash flow: −99.1%
Total debt: +322.7%

Quarter to September 2026, against a year earlier

192.35 14.70 +8.27%

Follow RVMD

Alert me

Market cap: $38.1B
P/E: 0.0×
Fwd P/E: −11.9×
Dividend yield: —
F-score: 4/9
Altman Z: 7.73
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Revolution Medicines, Inc. 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 5, 2026 · accepted 4:10 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2025: 40 added · 35 removed · 25 modified; 2 with only figures updated; 3 moved without change

Revolution Medicines, Inc. 10-Q filed Aug 5, 2026

What changed

Stockrow Weekly